de Lamballerie Xavier, Boisson V., Reynier J. C., Enault S., Charrel R. N., Flahault A., Roques P., Le Grand R. (2008). On chikungunya acute infection and chloroquine treatment. Vector-Borne and Zoonotic Diseases, 8 (6), p. 837-839. ISSN 1530-3667.
Titre du document
On chikungunya acute infection and chloroquine treatment
de Lamballerie Xavier, Boisson V., Reynier J. C., Enault S., Charrel R. N., Flahault A., Roques P., Le Grand R.
Source
Vector-Borne and Zoonotic Diseases, 2008,
8 (6), p. 837-839 ISSN 1530-3667
In recent issues, the efficacy of chloroquine (and the dosage that may be used) in the treatment of acute chikungunya infections was discussed. We have conducted a double-blind placebo-controlled randomized trial on the French Reunion Island (Indian Ocean), in which 27 patients received chloroquine and 27 patients received a placebo treatment. The chloroquine treatment consisted of 600 mg at day 1, 600 mg at days 2 and 3, and 300 mg at days 4 and 5. No significant difference between groups could be identified regarding the duration of febrile arthralgia or the decrease of viremia between day 1 and day 3. However, at day 200, patients who received chloroquine complained more frequently of arthralgia than those who received placebo (p < 0.01). In conclusion, Our results suggest that there is currently no justification for the use of chloroquine to treat acute chikungunya infections.
